Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001234068 | SCV001406694 | likely benign | CHARGE syndrome | 2025-01-23 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001556066 | SCV001777580 | likely benign | not provided | 2019-02-13 | criteria provided, single submitter | clinical testing | This variant is associated with the following publications: (PMID: 33270637) |
New York Genome Center | RCV001234068 | SCV002097898 | uncertain significance | CHARGE syndrome | 2021-02-09 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV003908453 | SCV004734799 | uncertain significance | CHD7-related disorder | 2023-11-16 | no assertion criteria provided | clinical testing | The CHD7 c.1696C>G variant is predicted to result in the amino acid substitution p.Pro566Ala. This variant was reported in an individual with pituitary stalk interruption syndrome (Brauner et al. 2020. PubMed ID: 33270637) and in an individual with a disorder of sexual development (Table S1, Zidoune et al. 2022. PubMed ID: 36110220). This variant is reported in 0.0035% of alleles in individuals of Latino descent in gnomAD, which may be too common to be a cause of disease. Although we suspect that this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |